45th week of 2010 patent applcation highlights part 45 |
Patent application number | Title | Published |
20100285996 | SEGMENTED PROCESS APPARATUS FOR MICROPLATE AND SEGMENTED PROCESS METHOD FOR MICROPLATE - An object is to provide a highly effective segmented process apparatus for a microplate using a standard microplate without increasing the scale of the apparatus, as well as a method for processing a microplate. The apparatus includes: a predetermined microplate provided with a number of wells are set in array; one or more nozzle heads provided with a number of nozzles set in array; a suction and ejection mechanism for sucking and ejecting a gas via the nozzles; and a moving means which allows relative movement between the microplate and the nozzle heads, wherein tips of all of the nozzles provided on each nozzle head are provided in such a manner that the tips can be inserted into the wells in a portion of the microplate all together, and the row intervals and column intervals of the nozzles in array are respectively same as the row intervals and column intervals of the wells in array. | 2010-11-11 |
20100285997 | PROBE MEDIUM - A probe medium for being placed on a substrate comprising a probe which can specifically bond to a target substance, and a substance having a site which can bond to the probe and a substance having a site which can bond to a substrate surface. A process for manufacturing a substrate an immobilized probe comprising the steps of providing a substrate, and providing the substrate with a probe medium comprising a probe which can specifically bond to a target substance and a substance having a site which can bond to the probe and a substance having a site which can bond to a substrate surface. Probe medium comprises a probe which can specifically bond to a target substance, a water-soluble polymer material, and a high boiling solvent. A process for immobilizing a probe comprising the steps of providing a substrate, and providing the substrate with probe medium comprising the probe which can specifically bond to a target substance, a water-soluble polymer material and a high boiling solvent. | 2010-11-11 |
20100285998 | POLYAMIDE BEADS AND METHOD FOR THE PRODUCTION THEREOF - Certain polyamide beads or granules are useful as a sustaining material for underground natural or artificial cracks of the earth's crust essentially employed for the extraction of hydrocarbons such as crude oil or natural gas; such polyamide beads have a spherical or ellipsoidal shape and have a surface free of concave portions, advantageously having a uniform shape, and having a mean diameter lower than or equal to 1.7 mm and a porosity lower than 0.1 ml/g, and are produced using a particular cutting device/extruder. | 2010-11-11 |
20100285999 | Treatment fluids for reduction of water blocks, Oil blocks, and/or gas condensates and associated methods - The present invention provides treatment fluids useful for subterranean operations, and more particularly, in at least one aspect, a treatment fluid that comprises a carrier fluid and a cationic surfactant comprising a cationic head group, a polar group attached to the head group, and a hydrophobic group that is either a saturated or unsaturated, branched or straight chain alkyl, and comprises about 6 carbons to about 22 carbons. The treatment fluids of the present invention are at least suitable for use as a remedial treatment for the reduction of existing water blocks, oil blocks, and/or gas condensates. | 2010-11-11 |
20100286000 | Nano-Sized Particle-Coated Proppants for Formation Fines Fixation in Proppant Packs - A fracturing fluid, gravel pack fluid and/or frac pack fluid containing particles such as proppants, gravel and/.or sand, may contain an effective amount of a nano-sized particulate additive to fixate or reduce fines migration, where the particulate additive is an alkaline earth metal oxide, alkaline earth metal hydroxide, alkali metal oxides, alkali metal hydroxides transition metal oxides, transition metal hydroxides, post-transition metal oxides, post-transition metal hydroxides piezoelectric crystals and pyroelectric crystals. The nano-sized particulate additive is optionally bound to the particles with a coating agent such as an oil, alcohol, glycol, glycol ethers, ketones, terpenes, etc. The particle size of the magnesium oxide or other agent may be nanometer scale but may be a larger scale than nanometer but still relatively small, which scale may provide unique particle charges that help fixate the formation fines. The carrier fluid used in the treating fluid may be aqueous, brine, alcoholic or hydrocarbon-based. | 2010-11-11 |
20100286001 | LITHIUM HYDROXIDE COMPOSITION, A PROCESS FOR PREPARING A LITHIUM HYDROXIDE COMPOSITION, AND A PROCESS FOR USING A LITHIUM HYDROXIDE COMPOSITION - The invention provides for a lithium hydroxide composition including lithium hydroxide, a base oil, and a polymer. The invention also provides for a process for preparing a lithium hydroxide composition including contacting a lithium hydroxide component, a base oil, and a polymer. The invention also provides for a process of using a lithium hydroxide composition for preparing a soap concentrate or a grease. | 2010-11-11 |
20100286002 | Engine Oil Formulations for Biodiesel Fuels - The lubricant for an internal combustion engine fueled by a biodiesel fuel (that is, a liquid fuel containing a C1-C4 alkyl ester of a carboxylic acid of about 12 to about 24 carbon atoms) exhibits improved resistance to oxidative degradation when the lubricant contains an alkali metal detergent. | 2010-11-11 |
20100286003 | Polymers with Pendant Heterocyclic-Containing Groups and Lubricating Oil Compositions Containing Same - The disclosed invention relates to polymers with heterocyclic-containing groups, and to concentrates and lubricating oil compositions containing the polymers. | 2010-11-11 |
20100286004 | LUBRICANT OIL ADDITIVE COMPOSITIONS - A lubricant oil composition having a synergistic oxidative stability is disclosed, the composition comprising at least one hindered phenolic antioxidant, at least one mono-boronated hindered phenolic antioxidant, at least one di-boronated hindered phenolic antioxidant, at least one alkylated diphenylamine and at least one organomolybdenum compound. The invention also provides a lubricating oil additive concentrate composition that imparts synergistic oxidative stability to a lubricant oil upon its addition, the concentrate composition comprising at least one hindered phenolic antioxidant, at least one mono-boronated hindered phenolic antioxidant, at least one di-boronated hindered phenolic antioxidant, at least one alkylated diphenylamine and at least one organomolybdenum compound. Further, the concentrate compositions of the present invention may also be prepared with a high concentration of hindered phenolic antioxidants without deleterious effects on viscosity or lubricant solubility. | 2010-11-11 |
20100286005 | DRY LUBRICANT FOR CONVEYING CONTAINERS - The passage of a container along a conveyor is lubricated by applying to the container or conveyor a mixture of a water-miscible silicone material and a water-miscible lubricant. The mixture can be applied in relatively low amounts, to provide thin, substantially non-dripping lubricating films. In contrast to dilute aqueous lubricants, the lubricants of the invention provide drier lubrication of the conveyors and containers, a cleaner conveyor line and reduced lubricant usage, thereby reducing waste, cleanup and disposal problems. | 2010-11-11 |
20100286006 | LUBRICANT FOR CONVEYING CONTAINERS - The passage of a container along a conveyor is lubricated by applying to the container or conveyor a lubricant composition comprising a water-miscible silicone material having a silicone emulsion wherein the silicone emulsion contains less than 500 ppm of a triethanolamine salts of alkyl benzene sulfonic acid compounds. | 2010-11-11 |
20100286007 | Tartaric Acid Derivatives as Fuel Economy Improvers and Antiwear Agents in Crankcase Oils and Preparation Thereof - Formulations using tartaric compounds of the present invention in a low sulfur, low ash and low phosphorous lubricant lower wear, and friction and improves fuel economy. | 2010-11-11 |
20100286008 | ADDITIVE FOR OILS AND LUBRICANT CONTAINING THE SAME - An additive for oils that is capable of imparting oils such as lubricant base oils or fuel oils with superior wear resistance properties or superior friction resistance properties and the like are provided. The additive for oils comprising a compound represented by formula (I): | 2010-11-11 |
20100286009 | Lubricant Composition - The invention refers to lubricant compositions, said lubricant compositions being particularly preferred for conveyor systems, especially in the foodstuff industry, which are suitable for lubricating, cleaning and disinfecting of the transport chains. More specifically, the invention refers to lubricant compositions for conveyor systems comprising: a) one or more phosphoric acid esters; and b) one or more ether carboxylates; and e) water; and c) one or more C | 2010-11-11 |
20100286010 | Ophthalmic Compositions with Hyaluronic Acid - An aqueous solution for cleaning and disinfecting a contact lens comprising 0.5 ppm to 5 ppm of 1,1′-hexamethylene-bis[5-(2-ethylhexyl)biguanide;
| 2010-11-11 |
20100286011 | PERSONAL CARE COMPOSITION IN THE FORM OF AN ARTICLE HAVING A POROUS, DISSOLVABLE SOLID STRUCTURE - The present invention relates to a dissolvable article in the form of a porous dissolvable solid structure, comprising from about 10% to about 50% water soluble polymer; from about 1% to about 25% plasticizer; from about 23% to about 75% surfactant; wherein said surfactants comprise one or more surfactants from Group I, wherein Group I includes anionic surfactants, and one or more surfactants from Group II, wherein Group II includes a surfactant selected from the group consisting of amphoteric, zwitterionic and combinations thereof; wherein the ratio of Group I to Group II surfactants is from about 5:95 to about 30:70; and wherein said dissolvable article has a density of from about 0.05 g/cm3 to about 0.40 g/cm3. | 2010-11-11 |
20100286012 | Cosmetic Material Removing Agent and Cosmetic Material Removing Device - There is provided a cosmetic material removing agent including an expansive clay mineral and a dextrin fatty acid ester. There is provided a cosmetic material removing device including the cosmetic material removing agent as described above and a container for containing and feeding the cosmetic material removing agent. | 2010-11-11 |
20100286013 | Chemical wipes - Wipes treated with organometallic compounds used in combination with organic acids in kit form, particularly organophosphorus acid, are disclosed. The kits can be used to treat various surfaces to alter the physical properties of the surfaces. | 2010-11-11 |
20100286014 | LOW PH POST-CMP RESIDUE REMOVAL COMPOSITION AND METHOD OF USE - An acidic composition and process for cleaning post-chemical mechanical polishing (CMP) residue and contaminants from a microelectronic device having said residue and contaminants thereon. The acidic composition includes surfactant, dispersing agent, sulfonic acid-containing hydrocarbon, and water. The composition achieves highly efficacious cleaning of the post-CMP residue and contaminant material from the surface of the microelectronic device without compromising the low-k dielectric material or the copper interconnect material. | 2010-11-11 |
20100286015 | AZEOTROPIC COMPOSITIONS COMPRISING FLUORINATED COMPOUNDS FOR CLEANING APPLICATIONS - The present invention relates to compositions comprising fluorinated olefins or fluorinated ketones, and at least one alcohol, halocarbon, hydrofluorocarbon, or fluoroether and combinations thereof. In one embodiment, these compositions are azeotropic or azeotrope-like. In another embodiment, these compositions are useful in cleaning applications as a degreasing agent or defluxing agent for removing oils and/or other residues from a surface. | 2010-11-11 |
20100286016 | Non-V.O.C. sprayable gel to remove insect bodies-environmentally friendly - This non-V.O.C. gel formula eliminates the need for harsh chemicals or environmentallly harmful solvents to remove dried dead bugs from windshields, headlights and vehicle grilles and bumpers. Prior art is to include solvents in the cleaning formula which can damage plastic headlight covers by making them hazy, or the use of detergents and scrub brushes or pads which can damage paint finishes and plastic components | 2010-11-11 |
20100286017 | Stain Treating Composition - A two-compartment dispenser comprises a first compartment, a second compartment and dispensing means. The first compartment contains an aqueous composition comprising a source of active oxygen and having a pH of greater than 0 but less than 7 and a perhydrolase enzyme. The second compartment contains an aqueous composition comprising an ester. The dispensing means is adapted to dispense the contents (or part thereof) of the compartments on to a surface either sequentially or simultaneously to form a mixture thereof. | 2010-11-11 |
20100286018 | SCENT-COMPRISING MICROCAPSULES WITH IMPROVED RELEASE BEHAVIOR - The present invention relates to microcapsules, microcapsule preparations, and detergents and cleaners comprising these, where the microcapsules comprise, in their core, one or more scents or fragrance(s) whose release behavior from the core of the microcapsules is considerably slowed through the use of more than one crosslinker. | 2010-11-11 |
20100286019 | Spray Drying Process - The present invention generally relates to particulate compositions and methods for making the compositions. It specifically relates to improved spray drying methods that substantially reduce the production of small particles that pose industrial hygiene concerns for factory workers and product consumers. In a composition aspect, the present invention provides an atomized aqueous composition. The composition is formed using a spray-drying apparatus. It includes 0.001 to 0.10 weight percent of a polymer, which is selected from a group consisting of a cellulose-based polymer, a gum, and a synthetic polymer. It further includes at least one polypeptide, which is present in the aqueous composition at a concentration greater than 0.01 weight percent. | 2010-11-11 |
20100286020 | MILK PROTEIN COMPOSITION AND USE THEREOF - A milk protein composition for use in treating or preventing chronic local inflammation in humans is disclosed. The invention also relates to the use of the milk protein composition for the manufacture of a nutritional composition and/or pharmaceutical composition for use in treating or preventing chronic local inflammation in humans. A nutritional composition, a pharmaceutical composition and a daily diet for treating or preventing chronic local inflammation in humans are also disclosed. | 2010-11-11 |
20100286021 | Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders - The invention is based on the discovery that an effective therapeutic strategy for ameliorating the symptoms of anxiety-related disorders can be achieved by decreasing levels of PK2 and administering an effective amount of PK2 receptor antagonist. A method of modulating the behavioral response of a subject displaying symptoms of stress responses and/or anxiety-related disorders is disclosed. The disclosed methods indicate that PK2 is an essential regulator of behavioral stress response independent of HPA. | 2010-11-11 |
20100286022 | EDIBLE AND BIOCOMPATIBLE METAL-ORGANIC FRAMEWORKS - The disclosure relates generally to materials that comprise organic frameworks. The disclosure also relates to materials that are useful to store and separate biological agents that are environmentally friendly and biocompatible. | 2010-11-11 |
20100286023 | Compositions and Methods for Increasing Muscle Mass, Strength, and Functional Performance in the Elderly - Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly by delivering a selection of amino acids, carnitine, and carboydrates with a low glycemic index. | 2010-11-11 |
20100286024 | Insulinotropic compounds and uses thereof - The invention provides novel GLP-1 analogues and compositions comprising such analogues. The compounds of the invention are useful in treating diabetes mellitus and related disorders. | 2010-11-11 |
20100286025 | SYNTHETIC APOLIPOPROTEIN E MIMICKING POLYPEPTIDES AND METHODS OF USE - The present invention provides novel synthetic apolipoprotein E (ApoE)-mimicking peptides wherein the receptor binding domain of apolipoprotein E is covalently linked to 18A, the well characterized lipid-associating model class A amphipathic helical peptide, or a modified version thereof. Such peptides enhance low density lipoprotein (LDL) and very low density lipoprotein (VLDL) binding to and degradation by fibroblast or HepG2 cells. Also provided are possible applications of the synthetic peptides in lowering human plasma LDL/VLDL cholesterol levels, thus inhibiting atherosclerosis. The present invention also relates to synthetic peptides that can improve HDL function and/or exert anti-inflammatory properties. | 2010-11-11 |
20100286026 | NOVEL PROTEIN - Provided is a novel, isolated polypeptide including an amino acid sequence of SEQ. ID. NO: 2 or SEQ. ID. NO: 4, and the nucleic acid molecule which encodes it. The polypeptide may be used in a method for treating various diseases including cancer, immune associated, viral and inflammatory diseases. | 2010-11-11 |
20100286027 | ANTI-BACTERIAL COMPOSITIONS - The invention relates to an isolated protein for use as an antimicrobial agent comprises a plurality of LRR (leucine rich repeat) domains, each LRR domain independently comprising an amino acid sequence of formula (I): (F1LxxLxL(xxZ) | 2010-11-11 |
20100286028 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp-Pro-Lys-Arg-Leu-Tyr as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp-Pro-Lys-Arg-Leu-Tyr optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-11-11 |
20100286029 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Tyr-Pro-Phe-Val-Glu-Pro-Ile-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Tyr-Pro-Phe-Val-Glu-Pro-Ile-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-11-11 |
20100286030 | NOVEL BACTERIOCIN FROM A NEW STREPTOMYCES SPECIES - Provided is an isolated novel Gram-positive non-motile, non-spore-forming, aerobic bacterium designated | 2010-11-11 |
20100286031 | Antibiotic Formulations, Unit Doses, Kits and Methods - An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the water solubility limit, at 25° C. and 1.0 atmosphere, of the anti-gram-positive antibiotic or salt thereof. Other embodiments include unit doses, kits, and methods. | 2010-11-11 |
20100286032 | PRODRUGS OF HIV PROTEASE INHIBITORS - A compound of the formula | 2010-11-11 |
20100286033 | NEW CYCLIC PEPTIDE COMPOUNDS - The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal. | 2010-11-11 |
20100286034 | USES FOR AQUEOUS STREAMS CONTAINING PROTEINS - The present invention relates to a protein hydrolysate comprising free amino acids and peptides whereby the weight ratio of free amino acids to peptides is about 1:1 and wherein at least about 50 molar % of the peptides has a molecular weight of 400 Da or less. This composition may be rich in one or more branched-chain amino acid-(BCAA-) and or glutamine-containing di- or tripeptides. Also, the invention relates to the use of a water soluble protein-containing aqueous fraction obtained from a wet-milling process or the protein hydrolysate in: the manufacture of a medicament for the treatment or prevention of a condition associated with inappropriate blood sugar metabolism; aiding recovery and/or endurance during or after exercise; stimulating the generation of lean body mass; infant nutrition; or the preparation of a food or feed composition or a food or feed supplement. | 2010-11-11 |
20100286035 | NEUROMEDIN U DERIVATIVE - The objective of the present invention is to provide a new antifeedant. The other objective of the present invention is to provide a NMU derivative showing a high antifeedant activity even in common administration forms such as peripheral administration. A neuromedin U derivative wherein a methoxypolyethylene glycol is bound via a linker having a specific structure to a polypeptide which contains at least 8 amino acids of the C-terminus of an amino acid sequence of neuromedin U and which consists of the same or substantially the same amino acid sequence as the amino acid sequence of neuromedin U. | 2010-11-11 |
20100286036 | NOVEL PEPTIDES THAT ENHANCE TIGHT JUNCTION PERMEABILITY - The present invention provides novel peptides that facilitate the opening of mammalian tight junctions, i.e. tight junction agonists. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide tight junction agonist of the invention in combination with a therapeutically effective amount of an active agent. | 2010-11-11 |
20100286037 | PHARMACEUTICAL AND/OR COSMETIC COMPOSITION CONTAINING ACTIVE-PRINCIPLE ACTIVATORS OF ACONITASE - The present invention relates to a cosmetic or pharmaceutical, and in particular dermatological, composition comprising, in a physiologically suitable medium, active ingredients capable of activating aconitase. These active ingredients may be polypeptides or peptides, used alone or in combination with at least one other active ingredient. The invention also relates to the use of a cosmetic composition which protects mitochondria. The invention also relates to a cosmetic treatment process for protecting the skin and the appendages against external attacks and for combating skin ageing. | 2010-11-11 |
20100286038 | FORMULATION CONTAINING CYCLIN-DEPENDENT KINASE INHIBITING COMPOUND AND METHOD OF TREATING TUMORS USING THE SAME - This application discloses a novel formulation containing a 3-amino-4-substituted pyrazole derivative which has cyclin-dependent kinase inhibiting properties, and a method of treating tumors using the novel formulation. | 2010-11-11 |
20100286039 | Use of SCF and G-CSF in the Treatment of Cerebral Ischemia and Neurological Disorders - The present invention relates to the use of stem cell factor (SCF) polypeptide, alone and in combination with granulocyte colony stimulating factor (G-CSF) polypeptide, in the prevention or treatment of injury to the brain after cerebral ischemia or neurological disorder. More particularly, the invention provides methods of improving neurological function and outcome after stroke by the administration of SCF polypeptide, alone and in combination with G-CSF polypeptide. This treatment can be used alone or in combination with other well-known methods of treatment of cerebral ischemia and neurological disorders in a mammal. | 2010-11-11 |
20100286040 | PRO-ANGIOGENIC PEPTIDES AND USES THEREOF - This present invention is directed to peptides, compositions, and methods for modulating endogenous cytokine expression in a subject. More specifically, the invention provides peptides useful in regulating the release of a specific pattern of cytokines that promote angiogenesis and/or can be used to modulate the immune system of a subject. | 2010-11-11 |
20100286041 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZ- OL-4(5H)-ONE - Invented is the compound (5Z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one, and/or pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are pharmaceutical compositions containing this compound, methods of preparing this compound and pharmaceutically acceptable salts, hydrates, solvates and pro-drugs thereof. Also invented are methods of using this compound as an inhibitor of hYAK3 proteins. | 2010-11-11 |
20100286042 | Medicinal Composition Containing Highly Functionalized Chimeric Protein - There is provided an FGF2 substitute containing medicinal composition which comprises, as an active ingredient, a chimeric protein comprising the amino acid sequence of an FGF1 protein in which a partial sequence including a sequence of at least positions 62-83 within a sequence of positions 41-83 is substituted with a partial sequence at the corresponding positions in the amino acid sequence of an FGF2 protein; and the remaining region is formed of the amino acid sequence of FGF1. In particular, this medicinal composition is used for wound healing and for the prevention and treatment of radiation-induced damage, and it exhibits a pharmacological action superior to that of an FGF2 medicinal composition, and further, it can be easily formulated into a preparation. | 2010-11-11 |
20100286043 | USE OF NEUREGULIN-1 IN REDUCING BRAIN DAMAGE - Methods of reducing and/or protecting against disorders in perinatal subjects are disclosed. Such methods can be used for disorders associated with neuronal cell damage. In certain aspects, the method comprises administering a therapeutically effective amount of neuregulin or a biologically active analog with a pharmaceutical carrier to a perinatal subject. In addition, the perinatal subject can be a fetus where the neuregulin is administered to the pregnant mother. Methods for assessing whether a perinatal subject is at risk for developing a neurological disorder are also disclosed. For example, expression levels of neuregulin can be used as an indication the perinatal subject is at risk for developing a disorder associated with neuronal cell damage. Evaluating the genotype of the NRG locus in a perinatal subject can also be used as an indicator of the risk of developing neurological disorders. | 2010-11-11 |
20100286044 | DETECTION OF TISSUE ORIGIN OF CANCER - Disclosed is a method for determining the cellular or tissue origin of tumor cells. The method entails determining the presence of at least one micro RNA (miRNA) in a sample derived from tumor tissue and based on the said determination establishing a miRNA expression profile and comparing this with pre-established miRNA expression profiles from cells, tissues or tumors. The determination uses short oligonucleotide probes comprising modified affinity-enhancing nucleobases. | 2010-11-11 |
20100286045 | METHODS COMPRISING DESMOPRESSIN - The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period. | 2010-11-11 |
20100286046 | MODIFIED H2 RELAXIN FOR TUMOR SUPPRESSION - Modified H2 relaxms which act as antagonists of the relaxm receptor in cells and tissues, in particular, modified H2 relaxms comprising one or more alterations of the ammo acid sequence at positions B 13, B17 and B20 located in the receptor binding domain The antagonists retain affinity to the receptor, but do not substantially activate the receptor once bound thereto The H2 relaxm antagonists are used in compositions and methods for the treatment of cancers wherein a relaxm receptor is expressed | 2010-11-11 |
20100286047 | USE OF VWF STABILIZED FVIII PREPARATIONS AND OF VWF PREPARATIONS WITHOUT FVIII FOR EXTRAVASCULAR ADMINISTRATION IN THE THERAPY AND PROPHYLACTIC TREATMENT OF BLEEDING DISORDERS - The present invention relates to the use of von Willebrand Factor (VWF) preparations or of a VWF preparation in combination with coagulation Factor VIII (FVIII) for extravascular administration in the therapy and prophylactic treatment of bleeding disorders. | 2010-11-11 |
20100286048 | Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention. | 2010-11-11 |
20100286049 | POLYCYSTIC KIDNEY DISEASE-RELATED GENE AND USE THEREOF - A major gene of a pc mutant of a Japanese Medaka fish ( | 2010-11-11 |
20100286050 | METHOD OF PREVENTING PROGRESSION OF HYPERTENSION-INDUCED HEART FAILURE WITH PKC PEPTIDES - Methods are described for slowing or inhibiting the progression of heart failure in a mammalian subject suffering from chronic hypertension. The methods involve administering an εPKC, β1PKC, or βIIPKC peptide inhibitor, examples of which are provided. | 2010-11-11 |
20100286051 | MEMORY AND LEARNING IMPAIRMENTS ASSOCIATED WITH DISRUPTION OF EPHRIN RECEPTOR A6 (EphA6) GENE - The present application is directed to a method of treating or preventing or ameliorating a neurological disorder associated with the disruption of a gene which encodes for an EphA6 polypeptide, the method comprising administering to a subject in need of such treatment whom may already have the disorder, or may be prone to have the disorder or may be in whom the disorder is to be prevented, a therapeutically effective amount of the therapeutic agent comprising a EphA6 polypeptide, or an agonist thereof, thereby effectively treating or preventing or ameliorating said disorder. | 2010-11-11 |
20100286052 | Novel use of antisecretory factor - The present invention relates to the use of an antisecretory protein or homologues thereof having the same properties, or certain fragments thereof in the manufacture of a medicament or a medical food for inducing improved rescue of injured or diseased nervous tissue, proliferation, apoptosis, differentiation and/or migration of an embryonic stem cell, adult stem cell, progenitor cell and/or a cell derived from a stem cell or progenitor cell, for treating a condition characterized by or associated with loss and/or gain of cells. In a preferred embodiment, the condition is a neurotrauma or a condition or disease of the CNS and/or PNS and/or ANS, for example, Alzheimer's disease. | 2010-11-11 |
20100286053 | PLASMINOGEN ACTIVATOR INHIBITOR AMELIORATION OF NEWBORN HYPOXIC ISCHEMIC BRAIN INJURY - Plasminogen activators as potential therapeutic targets in neonatal hypoxia ischemia (HI) brain injury. Use of plasminogen activator inhibitor-1 (PAI-1) to ameliorate HI encephalopathy related disease. Use of PAI-1 as preventive treatment of cerebral palsy (CP). | 2010-11-11 |
20100286054 | Composition - The present invention relates to a composition which comprises the following myelin basic protein peptides: MBP 30-44, MBP 83-99, MBP 131-145, and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods. | 2010-11-11 |
20100286055 | USE OF WNT3A FOR ACCELERATION OF WOUND HEALING - Provided is WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for accelerating wound healing. Also provided is a method of accelerating wound healing, the method comprising providing a therapeutically effective amount of WNT3 A, or a therapeutically effective fragment or derivative thereof, to a site where wound healing is to be accelerated. The medicaments and methods of the invention may be of particular use in accelerating the healing of skin wounds. | 2010-11-11 |
20100286056 | COMPOSITIONS FOR REDUCING OXIDATIVE STRESS AND USES THEREOF - The present invention relates to the use of one or more tripeptides selected from the group consisting of | 2010-11-11 |
20100286057 | METHODS AND COMPOSITIONS FOR MODULATING BCL-2 FAMILY POLYPEPTIDES - The present invention is based, at least in part, on the identification of a novel active site on BCL-2 family polypeptide such as BAX, which when bound by a compound, modifies the activity of the BCL-2 family polypeptide. | 2010-11-11 |
20100286058 | Assessing Chemotherapy Resistance of Colorectal Tumors by Determining Sparc Hypermethylation - Hypermethylation of the SPARC promoter is identified as a mechanism for repressing SPARC gene in cancer resulting in resistance to therapy. The restoration of SPARC expression with demethylating agents, such as 5-Aza-2′deoxycytidine, is shown to enhance chemosensitivity. The invention provides a mechanism of limiting the number of patients exposed to toxicity of demethylating agents by targeting its administration to the subset of patients with hypermethylation of the SPARC promoter. | 2010-11-11 |
20100286060 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOEITIN-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 2010-11-11 |
20100286061 | PLASMIN-INHIBITORY THERAPIES - The disclosure features a method of treating cancers, angiogenesis-related disorders and lymphangiogenesis-related disorders with plasmin inhibitors. An exemplary method includes: administering, to a subject, a plasmin inhibitor, such as a protein that includes a Kunitz domain that inhibits plasmin. | 2010-11-11 |
20100286062 | PHARMACEUTICAL COMPOUND - Provided is a compound comprising:
| 2010-11-11 |
20100286063 | GNRH agonist combination drugs - In the field of pharmaceuticals, it is intended to provide drugs whereby the preventive and therapeutic effects of a GnRH agonist on various diseases can be enhanced and QOL can be improved. More specifically, combination of drugs characterized in that the GnRH agonist is combined with a chemical selected from among SERM, SARM, sex hormone synthesis inhibitors, receptor-type tyrosine kinase inhibitors, bone metabolism regulators, drugs for immunotherapy, cytokine/chemokine inhibitors and endothelin receptor antagonists. Owing to these combinations, excellent effects of enhancing the preventive and therapeutic effects of the GnRH agonist on various diseases and relieving side effects can be established. Furthermore, QOL can be improved thereby. | 2010-11-11 |
20100286064 | POLYPEPTIDE INHIBITING TRANSMIGRATION OF LEUKOCYTES OR GROWTH AND/OR METASTASIS OF CANCER CELLS, AND FUSION PROTEIN THEREOF - The present invention provides a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, or a fusion protein thereof. The present invention also provides a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases including the polypeptide or a fusion protein thereof. The present invention also provides a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof. | 2010-11-11 |
20100286065 | TOPICAL METHODS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES AND CONDITIONS - The present invention relates to a new therapeutic approach for the treatment of eye diseases or conditions that allows for the delivery of corticosteroids to the eye's surface but does not cause any of the usual side effects associated with topical administration of corticosteroids. More specifically, the present invention provides methods of treatment involving the administration of a corticosteroid prodrug, such as dexamethasone palmitate, to the surface of the eye. Also provided are pharmaceutical compositions and kits for carrying out such methods of treatment. | 2010-11-11 |
20100286066 | Alpha 1-Antitrypsin Compositions and Treatment Methods Using Such Compositions - Alpha 1-antitrypsin compositions and treatment methods using such compositions for treating a variety of pulmonary diseases are provided. The compositions generally contain AAT, a stabilizing carbohydrate such as trehalose, a surfactant such as Polysorbate 80 and an antioxidant to stabilize AAT for use as a therapeutic. The formulations can be prepared as both liquids and solids and administered by nebulization of the liquid formulation or by conversion of dry powder formulation into an aerosol. | 2010-11-11 |
20100286067 | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES - The current invention provides polypeptides and polypeptide conjugates that include an exogenous N-linked glycosylation sequence. The N-linked glycosylation sequence is preferably a substrate for an oligosaccharyltransferase (e.g., bacterial PgIB), which can catalyze the transfer of a glycosyl moiety from a lipid-bound glycosyl donor molecule (e.g., a lipid-pyrophosphate-linked glycosyl moiety) to an asparagine (N) residue of the glycosylation sequence. In one example, the asparagine residue is part of an exogenous N-linked glycosylation sequence of the invention. The invention further provides methods of making the polypeptide conjugates that include contacting a polypeptide having an N-linked glycosylation sequence of the invention and a lipid-pyrophosphate-linked glycosyl moiety (or phospholipid-linked glycosyl moiety) in the presence of an oligosaccharyltransferase under conditions sufficient for the enzyme to transfer the glycosyl moiety to an asparagine residue of the N-linked glycosylation sequence. Exemplary glycosyl moieties that can be conjugated to the glycosylation sequence include GlcNAc, GlcNH, bacillosamine, 6-hydroybacillosamine, GalNAc, GaINH, GlcNAc-GlcNAc, GlcNAc-GlcNH, GlcNAc-Gal, GlcNAc-GlcNAc-Gal-Sia, GlcNAc-Gal-Sia, GlcNAc-GlcNAc-Man, and GlcNAc-GlcNAc-Man(Man)2. The transferred glycosyl moiety is optionally modified with a modifying group, such as a polymer (e.g., PEG). In one example, the modified glycosyl moiety is a GIcNAc or a sialic acid moiety. | 2010-11-11 |
20100286068 | MOLECULAR MARKERS OF PLANT EMBRYOGENESIS - The present invention relates generally to a molecular marker for a plant physiological process and more particularly for plant embryogenesis. The molecular marker is, in one form, a genetic sequence from a monocot plant such as but not limited to oil-palm plants. In another form, the molecular marker is a polypeptide encoded by said genetic sequence. More particularly, the molecular marker of the present invention enables embryogenic tissue to be detected in vitro. The early detection of embryogenic tissue enables non-embryogenic tissue to be discarded. The ability to detect embryogenesis facilitates maximization of embryogenic potential. The present invention further contemplates a molecular marker comprising in one form a sequence of nucleotides encoding an antioxidant or in another form a sequence of amino acids defining a polypeptide having antioxidant activity. The antioxidant according to this aspect of the present invention is particularly useful in tablet or cream form as an anti-aging agent. The molecular markers of the present invention therefore also have uses in the inhibition or retardation of apoptotic processes. Such an effect has benefits in both plant and animal cells. The present invention further contemplates a promoter sequence encoding the molecular marker and its use in generating male sterile plants. | 2010-11-11 |
20100286069 | CATIONIC PEPTIDE FOR DELIVERING AN AGENT INTO A CELL - There is presently provided a triblock peptide comprising a hydrophobic amino acid block, a histidine block and a cationic amino acid block. The triblock peptide may be used to form a nanoparticle for delivery of an agent into a cell. | 2010-11-11 |
20100286070 | AFFINITY TAG - The present invention relates to an affinity tag especially useful for human applications. The invention further includes methods for preparing fusion molecules, as well as compositions and reaction mixtures which contain said fusion molecules, nucleic acid molecules which encode these fusion molecules and recombinant host cells which contain these nucleic acid molecules. | 2010-11-11 |
20100286071 | Finger-1 Peptide Analogs of the TGF-Beta Superfamily - Members of the TGF-β superfamily and peptide fragments based on member proteins are employed to purify solutions containing member proteins or as therapeutics. | 2010-11-11 |
20100286072 | RETRO-INVERSO PEPTIDES DERIVED FROM INTERLEUKIN-6 - This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO: 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the same activity as native IL-6 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage. | 2010-11-11 |
20100286073 | COMPOUNDS AND METHODS FOR PHARMACEUTICAL USE - The present invention relates to compounds, as well as to compositions, methods and kits comprising such compounds, for use in the treatment or prophylaxis of fibromyalgia, chronic fatigue syndrome, myofascial pain syndrome, Gulf War syndrome and related conditions, wherein the compound is a fatty acid oxidation inhibitor and/or a carbohydrate oxidation activator. | 2010-11-11 |
20100286074 | PHARMACEUTICAL USE OF GINSENOSIDE OR MIXTURE THEREOF AND PHARMACEUTICAL COMPOSITION OF GINSENOSIDE AND USE THEREOF - The present invention provides a use of ginsenosides represented by formula I or mixtures thereof for manufacturing a medicament for anti-platelet aggregation, wherein R | 2010-11-11 |
20100286075 | AMPHIPHILIC BLOCK COPOLYMER MICELLE COMPOSITION CONTAINING TAXANE AND MANUFACTURING PROCESS OF THE SAME - A taxane-containing amphiphilic block copolymer micelle composition, including taxane, an amphiphilic block copolymer containing a hydrophilic block and a hydrophobic block, and an osmolality adjusting agent, is described. Also described are a method for preparing the same composition. The composition has excellent stability so that it can prevent rapid release of a drug and can improve a desired pharmacological effect. Additionally, the method enables highly efficient preparation of the composition. | 2010-11-11 |
20100286076 | ECTOPARASITICIDAL METHODS AND FORMULATIONS - Provided are novel methods and formulations for systemically controlling ectoparasite infestations in animals using spinetoram or a pharmaceutically acceptable salt thereof. | 2010-11-11 |
20100286077 | COMPOUNDS - The present invention provides a compound of formula (I′) which is a nystatin derivative having an additional double bond present between C28 and C29 and which is further modified relative to nystatin at one or more of positions C5, C7, C9, C10, C11, C16 or at the amino group of mycosamine. These compounds are used as anti-fungal agents. | 2010-11-11 |
20100286078 | TOPICAL OPHTHALMIC COMPOSITIONS CONTAINING TOBRAMYCIN AND DEXAMETHASONE - Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage. | 2010-11-11 |
20100286079 | COMPOSITION COMPRISING COVALENT CONJUGATES OF CHITOSAN AND AN ACIDIC DRUG AND PARENTERAL ADMINISTRATION - The present invention relates to a composition comprising an aqueous solvent and a conjugate of at least one hydrophilic polymer having a primary amine functional group, a derivative or monomer thereof and at least one acidic drug; a method for its preparation and use thereof. | 2010-11-11 |
20100286080 | AQUEOUS COMPOSITION COMPRISING CHITOSAN AND AN ACIDIC DRUG - The present invention relates to a composition comprising an aqueous solvent and a conjugate of at least one hydrophilic polymer having a primary amine functional group, a derivative or monomer thereof and at least one acidic drug; a method for its preparation and use thereof. | 2010-11-11 |
20100286081 | 5-AMINO-3-(2',3'-DI-O-ACETYL-BETA-D-RIBOFURANOSYL)-3H-THIAZOLO[4,5-D] PYRIMIDIN-2-OCE SALTS AND CRYSTALLINE FORMS - The invention relates to a maleate salt of 5-amino-3-(2′-3′-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and crystalline forms thereof, their production and usage, and pharmaceutical preparations containing these crystalline forms. | 2010-11-11 |
20100286082 | RIBOSWITCHES AND METHODS AND COMPOSITIONS FOR USE OF AND WITH RIBOSWITCHES - Riboswitches are targets for antibiotics and other small molecule therapies. Riboswitches and portions thereof can be used to regulate the expression or function of RNA molecules and other elements and molecules. Riboswitches and portions thereof can be used in a variety of other methods to, for example, identify or detect compounds. Compounds can be used to stimulate, active, inhibit and/or inactivate the riboswitch. Riboswitches and portions thereof, both alone and in combination with other nucleic acids, can be used in a variety of constructs and RNA molecules and can be encoded by nucleic acids. | 2010-11-11 |
20100286083 | NUCLEOSIDE ANALOGS - A purified compound having activity against hepatitis C virus is disclosed. | 2010-11-11 |
20100286084 | Oligomer-Nucleoside Phosphate Conjugates - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds. | 2010-11-11 |
20100286085 | NOVEL CHONDROITIN SULFATE HAVING DECREASED MOLECULAR WEIGHT AND USE THEREOF - An object of the present invention is to provide a chondroitin sulfate having a decreased molecular weight which has utilization as an inhibitor of peritoneal disorder caused by long-term use of a peritoneal dialysis fluid containing glucose or a polysaccharide thereof as an osmotic agent, utilization as an osmotic agent in a peritoneal dialysis fluid, and the like. The chondroitin sulfate having a decreased molecular weight of the present invention as a means for achieving the object is characterized by having a weight average molecular weight of from 1000 to 20000 and containing a constituent disaccharide unit represented by the following structural formula in an amount of from 65 o to 100% (molar ratio) of the total. | 2010-11-11 |
20100286086 | COMPOSITION FOR THE TREATMENT OF OSTEOARTHRITIS - The present invention relates to compositions comprising chondroitin sulphate and mannosamine or a derivative thereof. The mannosamine derivative is preferably N-acetylmannosamine. The compositions may comprise glucosamine. Said compositions are useful in the treatment or prevention of degenerative joint diseases, preferably of osteoarthritis, in the treatment or prevention of tendon or ligament diseases, disorders or injuries and of immune system diseases, preferably of rheumatoid arthritis. | 2010-11-11 |
20100286087 | PHARMACEUTICAL COMPOSITION, USE OF 2-IMINOPYRROLIDINE DERIVATIVE FOR PRODUCTION OF PHARMACEUTICAL COMPOSITION, AND KIT FOR TREATMENT OR AMELIORATION OF HEART DISEASES - One embodiment of the present invention is a pharmaceutical composition comprising at least one specific 2-iminopyrrolidine derivative and at least one other compound (B). Another embodiment of the present invention is a pharmaceutical composition comprising at least one specific 2-iminopyrrolidine derivative, which is to be used in combination with at least one other compound (B). According to the present invention, there are provided pharmaceutical compositions capable of treating or ameliorating diseases, such as heart diseases, effectively. | 2010-11-11 |
20100286088 | 3-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxy- lic Acid Amides and Their Use - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (collectively referred to herein as 3TM compounds). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds. | 2010-11-11 |
20100286089 | Process for the Preparation of Entecavir and Novel Intermediates Thereof Via Carbon-Silicon Oxidation - Processes for preparing entecavir and novel intermediates thereof using carbon-silicon oxidation. | 2010-11-11 |
20100286090 | Treatment of Multiple Myeloma - Methods for treating multiple myeloma comprising administering a therapeutically effective amount of dasatinib to a patient in need of treatment thereof. Dasatinib can be administered alone or in combination with a second anti-neoplastic agent such as dexamethasone or bortezomib. The patient may be refractory to prior treatment with an anti-neoplastic agent other than dasatinib. | 2010-11-11 |
20100286091 | IMIDAZOLIDINONE COMPOUNDS, METHODS TO INHIBIT DEUBIQUITINATION AND METHODS OF TREATMENT - The present invention features imidazolidinone compounds and pharmaceutical compositions of imidazolidinone compounds. The compounds of the invention are utilized in methods of treating a deubiquitination-related disorder in a subject and inhibiting p97-associated deubiquitination. | 2010-11-11 |
20100286092 | BETA-LACTAMASE INHIBITORS - Disclosed herein are α-aminoboronic acids and their derivatives which act as inhibitors of beta-lactamases. Also disclosed herein are pharmaceutical compositions comprising α-aminoboronic acids and methods of use thereof. | 2010-11-11 |
20100286093 | ANTI-INFLAMMATORY COMPOSITION CONTAINING DOCOSAHEXAENOYL LYSOPHOSPHATIDYLAMINE AS AN ACTIVE INGREDIENT - The present invention relates to an anti-inflammatory composition containing docosahexaenoyl lysophosphatidylamine as an active ingredient. Particularly, one of polyunsaturated lysophosphatidylcholines, docosahexaenoyl lysophosphatidylcholine inhibits intracellular NO generation mediated by lipopolysaccharide and suppresses zymosan A induced peritonitis in vivo, suggesting that it has excellent anti-inflammatory effect but has no cytotoxicity, so that it can be effectively used for prevention and treatment of inflammatory disease. | 2010-11-11 |
20100286094 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF - Conformationally constrained compounds that are novel and mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins and having bicyclic framework are disclosed, as well as their prodrugs. Such reverse-turn mimetic structures and pro-drugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. The invention also relates to a use of such compounds for the preparation of a medicament for treating or preventing cancer including an acute myeloid leukemia. | 2010-11-11 |
20100286095 | NOVEL USE OF A POLYAMINE-DEPLETED FOOD COMPOSITION FOR HUMAN OR VETERINARY USE, FOR PREPARING A THERAPEUTIC FOOD PRODUCT - A polyamine-depleted food compositions is provided for preparing foods, intended for humans or animals, for preventing or treating heart rate anomalies. | 2010-11-11 |
20100286096 | Methods of and Formulations for Reducing and Inhibiting the Growth of the Concentration of Microbes in Water-Based Fluids and Systems Used with Them - The present invention provides methods and formulations for reducing or inhibiting increase in the concentration of microbes in a water-based fluid. The methods and formulations of the present invention use an oxazolidine compound and a hydroxymethyl-substituted phosphorus compound selected from the group consisting of tetrakis(hydroxymethyl)phosphonium salts, C | 2010-11-11 |